Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin HIV AIDS. 2010 Sep;5(5):386-90. doi: 10.1097/COH.0b013e32833cfe4c.

Novel adenovirus vector-based vaccines for HIV-1.

Author information

  • Division of Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. dbarouch@bidmc.harvard.edu

Abstract

PURPOSE OF REVIEW:

Recombinant adenovirus (rAd) vectors have emerged as promising vaccine platform technologies due to their capacity to elicit potent humoral and cellular immune responses to encoded antigens. These vectors are being explored as potential vaccine candidates for a variety of pathogens. This review summarizes current efforts to develop rAd vector-based vaccines for HIV-1.

RECENT FINDINGS:

In the phase 2b Step study, rAd5 vectors expressing clade B HIV-1 Gag, Pol, and Nef antigens failed to afford protection and may have resulted in increased HIV-1 acquisition in certain subgroups. Recent studies have explored the potential reasons for this failure and the utility of novel rAd vectors derived from non-Ad5 serotypes.

SUMMARY:

Current areas of active investigation include the development of alternative serotype rAd vectors, the incorporation of rAd vectors into heterologous vector prime-boost regimens, and the use of rAd vectors to express novel HIV-1 antigens. These HIV-1 vaccine candidates will be evaluated in clinical trials over the next several years.

PMID:
20978378
[PubMed - indexed for MEDLINE]
PMCID:
PMC2967414
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins Icon for PubMed Central
    Loading ...
    Write to the Help Desk